changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
An open-label, prospective, multicenter, randomized, Phase III clinical trial evaluating yttrium-90 transarterial radioembolization (TheraSphere®) in the treatment of patients with unresectable hepatocellular carcinoma (HCC).27,28
TheraSphere® prior to initiation of standard-of-care therapy: sorafenib
Standard-of-care therapy: sorafenib
To evaluate the efficacy and safety of TheraSphere® in patients with unresectable HCC in whom treatment with sorafenib is planned.
Primary: Overall survival
Secondary: Time to progression, tumor response, time to symptomatic progression, quality of life (FACT-hep), time to untreatable progression, safety
Please visit the THERASPHERE TRIALS WEBSITE for more details
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com